Last reviewed · How we verify
Comparator: pranlukast
Pranlukast is a cysteinyl leukotriene receptor antagonist that blocks the inflammatory effects of leukotrienes in the airways.
Pranlukast is a cysteinyl leukotriene receptor antagonist that blocks the inflammatory effects of leukotrienes in the airways. Used for Asthma (allergic and exercise-induced), Allergic rhinitis.
At a glance
| Generic name | Comparator: pranlukast |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Cysteinyl leukotriene receptor antagonist |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
Pranlukast selectively antagonizes cysteinyl leukotriene receptors (CysLT1), preventing the binding of leukotrienes (LTC4, LTD4, LTE4) that are released during allergic and inflammatory responses. By blocking these receptors, it reduces airway inflammation, mucus secretion, and bronchoconstriction, thereby improving airflow and reducing asthma symptoms.
Approved indications
- Asthma (allergic and exercise-induced)
- Allergic rhinitis
Common side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |